A phase I study with oral SU5416 in patients with advanced solid tumors: A drug inducing its clearance

Investigational New Drugs

Volumn 24, Issue 4, 2006, Pages 299-304

  Salzberg, Marc ^a,b   Pless, Miklos ^a   Rochlitz, Christoph ^a   Ambrus, Klara ^a   Scigalla, Paul ^b   Herrmann, Richard ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b PFIZER INC   (United States)

Author keywords

Anti angiogenesis; Inhibition neovascularization; Nanocrystal Colloidal Dispersion; SU5416; Tyrosine kinase; VEGF

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; NANOCRYSTAL COLLOIDAL DISPERSION SU5416; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ADVANCED CANCER; AGED; ANGIOGENESIS; AREA UNDER THE CURVE; ARTICLE; ASPHYXIA; BACKACHE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG ACTIVITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG FORMULATION; DRUG METABOLISM; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; HEMATOMA; HUMAN; INJECTION SITE PAIN; MALE; NARCOLEPSY; NAUSEA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SOLID TUMOR; URINE INCONTINENCE; VOMITING; WEAKNESS;

ADMINISTRATION, ORAL; ADULT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDOLES; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRROLES;

EID: 33646515151     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-005-4061-z     Document Type: Article

References (17)

1. Folkman J: Antiangiogenic therapy. In: de Vita VT Jr, Hellman S, Rosenberg SA (eds.): Cancer: Principles and practice of oncology, 5th edn. Philadelphia, PA: Lippincott-Raven, 3075-3085, 1997
2. Berlin JD: Targeting vascular endothelial growth factor in colorectal cancer. Oncol Suppl 16(8): 13-15, 2002
3. Lee JC, Chow NH, Wang ST, et al.: Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 36: 748-753, 2000
4. Pinedo HM, Slamon J: Translational Research: The role of VEGF in tumor angiogenesis. Oncologist 5: 1-2, 2000
5. Ferrara N: Role of Vascular Endothelial Growth Factor in physiologic and pathologic angiogenesis: therapeutic implications. Sem Oncol 29(6), (Suppl. 16): 10-14, 2002
6. Kabbinavar F, Hurwitz H, Fehrenbacher L, Meropol N, Novotny W, Lieberman G, et al.: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)(leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21(1): 60-65, 2003
7. Fong TA, Shawver LK, Sun L, et al.: SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59: 99-106, 1999
8. Sukbuntherng J, Cropp G, Hannah A, Wagner G, Shawver L, Antonian L: Pharmacokinetics and Interspecies Scaling of a novel VEGF receptor inhibitor, SU5416. J Pharmacy Pharmacol 53: 1629-1636, 2001
9. Salzberg M, Pless M, Rochlitz C, Scigalla P, Herrmann R: A phase I and pharmacokinetic study of oral administration of SU5416 in patients with advanced solid tumors. Presentation at poster workshop session on Phase I/Clinical Pharmacology ECCO 2003, Copenhagen
10. Antonian L, Zhang H, Yang C, Wagner G, Shawver L, Shet M, et al.: Biotransformation of the Anti-Angiogenic compound SU5416. Drug Metab Disposit 28: 1505-1512, 2000
11. Ogilvie, Scheinkönig JA, Antonian L, Ye C, Tan W, Madan A, Parkinson A: SU5416 undergoes concerted (two-step) oxidation by human CYP1A2 to an alcohol and then the corresponding carboxylic. Drug Metab Rev 23(S1): 111, 2002
12. Internal Sugen Data onFile
13. Raeissi SD, Waltz K, Sukbuntherng J, Lipson K, Sweeney D, Kim TW, Antonian L: In vitro model to elucidate the potential of the receptor of the receptor tyrosine kinase (RTK) inhibitor SU5416 to induce CYP1A1. Proc Am Ass Cancer Res 42: 190, 2001
14. Solis WA, Wong SGW, Vela J, Antonian, Sweeney DJ: Investigation into the mechanism of CYP1A1 induction by indolinone receptor tyrosine kinase inhibitors. Presented in IUPHAR, San Francisco, CA, 7/2002
15. Stoppeck A, Sheldon M, Vahedian M, Cropp G, Gosalia R, Hannah A: Results of a phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clin Cancer Res 8:2798-2805, 2002
16. Mendel D, Schreck R, West DC, Li G, Strawn L, Tanciongco S, et al.: The angiogenesis inhibitor SU5416 has long lasting effects on VEGF receptor phosphorylation and function. Clin Cancer Res 6: 4848-4858, 2000
17. Laird A, Vajkoczy P, Shawver L, Thurnher A, Liang C, et al.: SU6668 is a potent anti-angiogenic and anti-tumor agent which induces regression of established tumors. Cancerv Res 60: 4152-4160, 2000